<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00286312</url>
  </required_header>
  <id_info>
    <org_study_id>RDC-2005-02</org_study_id>
    <nct_id>NCT00286312</nct_id>
  </id_info>
  <brief_title>Myocardial Infarction Size Reduction With Atorvastatin</brief_title>
  <official_title>Prevention of Reperfusion Damage and Late Left Ventricular Remodelling With Atorvastatin Administered Before Reperfusion Therapy. The REPERATOR Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R&amp;D Cardiologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>R&amp;D Cardiologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if oral atorvastatin administered just before&#xD;
      percutaneous coronary angioplasty for acute myocardial infarction improves early and late&#xD;
      heart function as compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Left ventricular remodelling after a myocardial infarction refers to changes in shape and&#xD;
      function of the infarcted and uninfarcted myocardium. Remodelling begins minutes after acute&#xD;
      myocardial infarction and may continue for months or years, leading to dilation of the left&#xD;
      ventricle (LV) and an increased LV volume. As studies show, LV volume strongly correlates&#xD;
      with long-term mortality. Reperfusion after a period of ischaemia (through medication or&#xD;
      PTCA) leads to so-called 'reperfusion injury'. This results in myocardial dysfunction and&#xD;
      damage, which can lead to LV remodelling.&#xD;
&#xD;
      In a study where atorvastatin was administered at the onset of reperfusion infarct size was&#xD;
      reduced. Atorvastatin led to protection of the reperfused myocardium, independently of its&#xD;
      effects on cholesterol.&#xD;
&#xD;
      The objective is to measure the effect of atorvastatin, administered orally before&#xD;
      reperfusion therapy by PTCA, on infarct size and microvascular reperfusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular end systolic volume index as measured by cine magnetic resonance imaging (MRI) at 3 month follow-up</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other MRI measurements of global and regional left ventricular function</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI measurements of infarct size at admission, 1 week, and 3 months, as well as changes in these measures between MRI investigations</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical markers of infarct size</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blush grade</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Reperfusion Injury</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive patients (aged &gt; 18 years) who are to undergo a primary PCI for a first&#xD;
             acute ST elevation myocardial infarction will be asked to participate in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous myocardial infarction&#xD;
&#xD;
          -  Previous coronary artery bypass grafting (CABG)&#xD;
&#xD;
          -  Cardiac rhythm is other than normal sinus rhythm.&#xD;
&#xD;
          -  Electrical instability.&#xD;
&#xD;
          -  The patient is in Killip class 3 or 4 of heart failure.&#xD;
&#xD;
          -  Need for intra aortic balloon counterpulsation therapy&#xD;
&#xD;
          -  The patient is unable to hold his/her breath for up to 20 seconds due to age or&#xD;
             concomitant illness.&#xD;
&#xD;
          -  Implanted electronic devices are present: pacemakers, internal defibrillators,&#xD;
             ECG-registration devices, neurostimulators, implanted drug infusion devices, cochlear&#xD;
             implants etc.&#xD;
&#xD;
          -  Previous vascular surgery: aneurysm clip, carotid artery vascular clamp, aortic clips,&#xD;
             or venous umbrella&#xD;
&#xD;
          -  Prosthesis (orbital/penile, etc.)&#xD;
&#xD;
          -  Spinal/intra-ventricular shunts.&#xD;
&#xD;
          -  Swan-Ganz catheter; transdermal delivery systems.&#xD;
&#xD;
          -  Metal fragments: eye, head, ear, skin.&#xD;
&#xD;
          -  Implants held by magnets.&#xD;
&#xD;
          -  Known allergy to MR contrast media&#xD;
&#xD;
          -  Prior use of statins&#xD;
&#xD;
          -  No PCI performed&#xD;
&#xD;
          -  No recanalisation achieved&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benno Rensing, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Ziekenhuis Nieuwegein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>February 2, 2006</study_first_submitted>
  <study_first_submitted_qc>February 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2006</study_first_posted>
  <last_update_submitted>May 20, 2008</last_update_submitted>
  <last_update_submitted_qc>May 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2008</last_update_posted>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Primary angioplasty</keyword>
  <keyword>Reperfusion damage</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Placebo</keyword>
  <keyword>Early left ventricular remodelling</keyword>
  <keyword>Late left ventricular remodelling</keyword>
  <keyword>Cardiac MRI</keyword>
  <keyword>Statin</keyword>
  <keyword>Transluminal, Percutaneous Coronary</keyword>
  <keyword>Angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

